UCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trial

UCB's drug, Bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an investigator, according to the Belgium-based company.

New Delhi: UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease.

UCB's drug, Bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an investigator, according to the Belgium-based company.

The latest study was the third positive late-stage trial of the drug, following data reported last month and in October.

Read Also: AbbVie says multiple parties vying for assets related to Allergan deal approval

The company said it would apply for the drug's approval with the regulators in mid-2020.

AbbVie's Humira is the world's top-selling drug and treats rheumatoid arthritis and psoriasis.

Read Also: Cipla Gulf, Alvotech partner to commercialise AVT02 Biosimilar of AbbVie’s Blockbuster drug Humira